SCHEMBL2117577

SCHEMBL2117577

COc1ccc(-c2ccc(C)c(NS(=O)(=O)c3cc(OC)c(C)s3)c2)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.45
ALDH1A1 P00352 2/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
POLB P06746 1/20 0.40
MAPK1 P28482 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TP53 P04637 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KEAP1 Q14145 1/20 0.38
AKT1 P31749 2/20 0.37
MTOR P42345 2/20 0.37
PIK3CA P42336 1/20 0.37
SHMT2 P34897 1/20 0.37
PTGER4 P35408 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2117509 0.86 ACLY (0.42) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL2119497 0.85 MAPT (0.44) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL2120135 0.82 KMT2A (0.56) MAPTALDH1A1POLBKDM4EMEN1
SCHEMBL2118122 0.82 MAPT (0.48) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL2117812 0.78 MAPT (0.48) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL2119623 0.78 GHSR (0.45) MAPTALDH1A1POLBKDM4EMEN1
SCHEMBL2120161 0.78 MAPT (0.54) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL2117841 0.78 MAPT (0.54) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL2119462 0.78 LMNA (0.55) MAPTALDH1A1CYP2C9TSHRNPSR1
SCHEMBL2119232 0.78 MAPT (0.45) MAPTALDH1A1CYP2C9TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 MAPT 4747/4885ALDH1A1 1063/4885CYP2C9 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.